Source link : https://www.newshealth.biz/health-news/cendakimab-shows-promise-in-eosinophilic-esophagitis/
VIENNA — Cendakimab, a monoclonal antibody targeting interleukin (IL) 13, improved symptoms and reduced esophageal eosinophil counts in adult and adolescent patients with eosinophilic esophagitis (EoE), according to interim results of a pivotal phase 3 trial. Treatment with cendakimab also improved key endoscopic and histologic features, even in patients who had an inadequate response or […]
Author : News Health
Publish date : 2024-10-18 10:00:48
Copyright for syndicated content belongs to the linked Source.
Categories